IncellDx technology combines a unique multiplex RNA in situ hybridization method called Simultaneous Ultrasensitive Signal-amplified Hybridization In Situ (SUSHI) with a novel, cell-based instrument capable of quantifying multiple proteins and molecular biomarkers inside intact cells. This allows protein and gene expression to be measured by distinct cell type which aids both diagnosis and disease localization. The company currently has more than 30 issued and pending patents.
The technology is ultra-fast, inexpensive, highly reproducible, and able to perform complex molecular testing without DNA extraction or amplification.
ESMO 2017 – September 8-12, 2017
IncellDx will be at ESMO 2017.
Come visit us at booth 117.
Eurogin Meeting 2017 – October 8-11, 2017
IncellDx will be at Eurogin 2017.
More information to come.
No Positions Available at This Time
CEO & Founder
Dr. Patterson received his undergraduate training in molecular biology from the University of Michigan in Ann Arbor. He then went on to Northwestern University Medical School for training in medicine. During the early stages of the AIDS epidemic, Dr. Patterson began investigating cellular reservoirs of HIV-1 using molecular and in situ technology patented in his laboratory. Dr. Patterson went on to a residency in Pathology focusing on viral pathogenesis. While in his residency, Dr. Patterson determined that enough HIV virus was present in infected individuals to account for the massive destruction of the immune system. This paradigm altering work was published in Science in 1993. Dr. Patterson later was named Chief Resident of Pathology at Northwestern Memorial Hospital. Dr. Patterson has authored over 100 manuscripts and book chapters and he continues his work on HIV-1 pathogenesis and reservoirs at Stanford University School of Medicine. Dr. Patterson was the Medical Director of Diagnostic Virology at Stanford University Hospitals and Clinics.
Chief Operating Officer
As Chief Operating Officer, Eric Hass brings over twenty years general management experience to IncellDx. Previously, he served as CEO or COO of six high technology companies, including Rangestar Wireless (micro antennas for mobile communications and computing), Maginet Corporation (in-room hotel entertainment and information systems), Sunflex Company (computer accessories), Oktel Corporation (extremely high transfer rate disk drives for medical x-ray recording and intelligence analysis), Victor Technologies (microcomputers and business equipment), and Source Technologies (business presentation systems). Earlier, he was a senior executive with Spectra-Physics, serving as European Marketing Manager, and then as General Manager of the Component Laser, Laser Instruments and Optics Divisions. Mr. Hass received his B.A. from Claremont McKenna College and his M.B.A. from the University of Southern California. He has served on the Board of numerous high technology companies.
Chief Technical Officer
Grace has over twenty years experience in Research & Development and Manufacturing Management in the Medical Device industry. She previously served as Project Manager for Dako, leading international product development teams to launch biological reagents and instrument systems. Earlier, she was responsible for the manufacture and quality control of all molecular pathology reagents manufactured by Dako North America, and has led numerous cross-disciplinary teams to develop molecular pathology probes and detection systems. Knutson previously held staff research positions in virology research laboratories at University of California Santa Barbara and USC Medical School. She received her BA from the University of California at Santa Barbara, and holds a Project Management Professional (PMP®) credential.
Chief Business Officer
As Chief Business Officer, Chris Meda has thirty years of leadership in the diagnostic and pharmaceutical industries. Her management responsibilities have included the creation of strategic business direction and plans; operations and commercialization of more than thirty products for various disease areas at Hoffman-LaRoche, Bio-Rad Laboratories, Diagnostics Products Corporation (now Siemens), Meridian Diagnostics and Schering AG pharmaceuticals. Chris also serves as a Chair on Women in BIO – San Francisco Chapter, an organization of professionals committed to promoting careers, leadership, and entrepreneurship of women in the life sciences; and as Board Director for Claremont BioSolutions, a company providing laboratories with diagnostics and devices for molecular diagnostics and bioscience research. Prior to IncellDx, Chris was President of Response Genetics (RGI), a precision medicine company that has developed PCR-based genetics tests for lung, colon, gastric and melanoma cancers.
The CEO of IncellDx has issued the following Quality Policy Statement:
IncellDx is committed to developing, manufacturing and distributing products that are of the highest quality available to our customers. To that end, we are committed to meeting or exceeding all applicable regulatory requirements as well as our customers’ requirements. We believe that the long-term success of our business relies on incorporating the quality objectives of both entities of the manufacturer – customer relationship. In order to achieve our objectives, our management team and all IncellDx employees are dedicated to continually improving our products, processes and services at all levels of the organization.